#151869

Anti-LRAT [M34-P1F10]

Cat. #151869

Anti-LRAT [M34-P1F10]

Cat. #: 151869

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Lecithin Retinol Acyltransferase (LRAT)

Class: Monoclonal

Application: ELISA ; IHC ; IF ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-LRAT [M34-P1F10]
  • Clone: M34-P1F10
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; IF ; WB
  • Description: LRAT is significantly overexpressed in colorectal cancer and significantly associated with prognosis.
  • Immunogen: Peptide Sequence - RDQRSVLASA (amino acids 190 -199)
  • Isotype: IgG1
  • Recommended controls: ELISA- Peptide immunogenWestern Blot- Overexpression lysate Immunofluorescence- Hela Cells IHC- Human colon carcinoma

Target Details

  • Target: Lecithin Retinol Acyltransferase (LRAT)
  • Tissue cell line specificity: ELISA- Peptide immunogenWestern Blot- Overexpression lysate Immunofluorescence- Hela Cells IHC- Human colon carcinoma
  • Target background: LRAT is significantly overexpressed in colorectal cancer and significantly associated with prognosis.

Applications

  • Application: ELISA ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.
  • The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.